P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY)

• H. C. Lee,
• K. Ramasamy,
• M. Macro,
• F. E. Davies,
• R. Abonour,
• F. van Rhee,
• V. T. Hungria,
• N. Puig,
• K. Ren,
• J. Silar,
• V. Enwemadu,
• D. Cherepanov,
• D. M. Stull,
• X. Leleu

Affiliations

H. C. Lee

1 MD Anderson Cancer Center, Houston, United States of America

K. Ramasamy

2 Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

M. Macro

3 CHU de Caen, Caen, France

F. E. Davies

4 Perlmutter Cancer Center, NYU Langone, New York

R. Abonour

5 Indiana University School of Medicine, Indianapolis

F. van Rhee

6 University of Arkansas for Medical Sciences, Little Rock, United States of America

V. T. Hungria

7 Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil

N. Puig

8 Hospital Universitario de Salamanca Hematología, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

K. Ren

9 Takeda Development Center Americas, Inc. (TDCA), Lexington, United States of America

J. Silar

10 Institute of Biostatistics & Analyses, Ltd, Brno, Czechia

V. Enwemadu

11 Takeda Pharmaceuticals U.S.A., Inc., Lexington, United States of America

D. Cherepanov

9 Takeda Development Center Americas, Inc. (TDCA), Lexington, United States of America

D. M. Stull

11 Takeda Pharmaceuticals U.S.A., Inc., Lexington, United States of America

X. Leleu

12 Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, France